Answers are grounded in this paper and cite their sources.
Despite prophylactic immunosuppression the incidence of acute graft-versus-host disease (aGVHD) after allogeneic stem cell transplantation ranges from 30% to 70%. Systemic corticosteroids are the accepted first-line therapy but no consensus exists about secondary treatment in lack of controlled trials, and patients who fail initial therapy have mortality rates up to 90%.1,2 α-1-antitrypsin (AAT), a serine protease inhibitor with anti-inflammatory properties, has been shown to reduce the severity of experimental and, more recently, also clinical aGVHD.3,4 Patient 1 A 68-year-old female AML patient received an HLA-identical unrelated peripheral blood stem cell transplantation after reduced-intensity conditioning. By day +25, aGVHD grade II (skin, upper gastrointestinal [GI] tract) was diagnosed clinically and was treated with methylprednisolone 2 mg/kg per day. Despite clinical improvement, a spontaneous colon perforation on day +33 required surgical intervention. Histology confirmed the diagnosis of GI-aGVHD with mucosal denudation and ulceration (Lerner score, 3-4) without other clinical symptoms of aGVHD at this time.5 Intermittent cytomegaly virus (CMV) antigenemia was successfully treated with ganciclovir and steroids were tapered. Around day +60, the patient developed severe abdominal pain and bloody diarrhea greater than 1 L/d. Extensive ulcerative terminal ileitis was diagnosed by endoscopy with typical histological signs of severe GI-aGVHD.5 Steroid dose was increased to 1 g/d for 3 consecutive days along with topical budesonide without improvement of symptoms. On day +79, intravenous AAT (Prolastin) was initiated at a dosage of 60 mg/kg twice weekly for a total of 7 doses. Despite transient clinical improvement and a continuous decrease of fecal calprotectin after the fifth AAT infusion (Figure 1B), the patient deteriorated and finally died on day +108 of GI bleeding.FIGURE 1: AAT improves the course of steroid-refractory acute GI-GVHD. A, Representative H&E stainings of terminal ileum and transverse colon before and after AAT treatment from patient 2 (original magnification, ×400, scale bars, 50 μm). B, Fecal calprotectin levels during AAT treatment from both patients. qod, every other day; H&E, hematoxylin-eosin.Patient 2 A 55-year-old AML patient well engrafted after an HLA-identical, myeloablative sibling peripheral blood stem cell transplantation was readmitted on day +27 because of severe watery diarrhea greater than 1 L/d. Stool cultures remained negative and terminal ileitis and colitis was diagnosed by endoscopy. Histology confirmed the diagnosis of GI-aGVHD (Lerner score, 2-4).5 Treatment with methylprednisolone 2 mg/kg per day and topical budesonide was initiated without any improvement. Seven days later, intravenous AAT was started (60 mg/kg per day, every other day for 8 doses). The clinical response, particularly improvement of diarrhea and decrease of fecal calprotectin despite steroid tapering, was further confirmed by endoscopy at the end of AAT treatment showing improved histological features of the ileum and colon (Figure 1). CMV antigenemia, first documented 7 days after the last AAT infusion, was successfully treated with valganciclovir. We here report on our experience with AAT as a second-line treatment in 2 patients with steroid-refractory GI-aGVHD. Although patient 1 after a transient clinical improvement finally died of GI bleeding, patient 2 showed a sustained and complete response. We observed a decrease of fecal calprotectin in both patients, although delayed in patient 1 presumably due the dosing schedule of only twice weekly; fecal calprotectin is an established marker for intestinal inflammation and predictive for response to steroids at the time of diagnosis of GI-GvHD.6,7 However, its value for monitoring a treatment response during AAT remains to be determined. Whether the risk of CMV infection/disease is increased by AAT treatment or results from steroid pretreatment is unknown. At least in a small series on 12 patients recently published by the Seattle group (clinicaltrials.gov: NCT01523821), clinically relevant toxicities were not reported.4 Further studies on this potentially highly active treatment option are greatly warranted.
No takes yet. Share an insight, caveat, or question.
Gerner et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: